Healthcare provider profile · identity verified

Michael Konopacki, M.D.

Family Practice · BOERNE, TX · NPI 1487817102

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	587	172
Rosuvastatin Calcium	Rosuvastatin Calcium	498	160
Levothyroxine Sodium	Levothyroxine Sodium	464	134
Amlodipine Besylate	Amlodipine Besylate	392	127
Lisinopril	Lisinopril	359	110
Losartan Potassium	Losartan Potassium	336	104
Tamsulosin Hcl	Tamsulosin Hcl	336	101
Metformin Hcl	Metformin Hcl	242	74
Zolpidem Tartrate	Zolpidem Tartrate	237	43
Gabapentin	Gabapentin	228	72
Pantoprazole Sodium	Pantoprazole Sodium	228	76
Omeprazole	Omeprazole	221	68
Metoprolol Succinate	Metoprolol Succinate	184	54
Hydrochlorothiazide	Hydrochlorothiazide	150	50
Eliquis	Apixaban	147	40
Furosemide	Furosemide	136	46
Simvastatin	Simvastatin	135	41
Clonazepam	Clonazepam	130	22
Alprazolam	Alprazolam	129	38
Allopurinol	Allopurinol	127	41
Prednisone	Prednisone	125	103
Glipizide Er	Glipizide	123	35
Ramipril	Ramipril	123	42
Pravastatin Sodium	Pravastatin Sodium	117	35
Sertraline Hcl	Sertraline Hcl	116	28
Ozempic	Semaglutide	112	21
Finasteride	Finasteride	110	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	110	25
Azithromycin	Azithromycin	107	94
Tramadol Hcl	Tramadol Hcl	105	29
Montelukast Sodium	Montelukast Sodium	103	33
Chlorthalidone	Chlorthalidone	101	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	100	31
Metoprolol Tartrate	Metoprolol Tartrate	100	36
Carvedilol	Carvedilol	99	33
Meloxicam	Meloxicam	99	31
Fluoxetine Hcl	Fluoxetine Hcl	98	27
Olmesartan Medoxomil	Olmesartan Medoxomil	97	25
Ciprofloxacin Hcl	Ciprofloxacin Hcl	96	72
Trazodone Hcl	Trazodone Hcl	95	27
Famotidine	Famotidine	94	20
Duloxetine Hcl	Duloxetine Hcl	83	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	79	26
Fluticasone Propionate	Fluticasone Propionate	78	31
Albuterol Sulfate Hfa	Albuterol Sulfate	76	30
Escitalopram Oxalate	Escitalopram Oxalate	75	20
Januvia	Sitagliptin Phosphate	70	14
Synthroid	Levothyroxine Sodium	70	16
Clopidogrel	Clopidogrel Bisulfate	68	24
Jardiance	Empagliflozin	65	14
Bupropion Xl	Bupropion Hcl	63	22
Warfarin Sodium	Warfarin Sodium	63	suppressed
Citalopram Hbr	Citalopram Hydrobromide	60	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	60	18
Spironolactone	Spironolactone	60	16
Lorazepam	Lorazepam	55	15
Oxybutynin Chloride Er	Oxybutynin Chloride	55	19
Celecoxib	Celecoxib	54	14
Pregabalin	Pregabalin	53	19
Triamcinolone Acetonide	Triamcinolone Acetonide	50	37
Donepezil Hcl	Donepezil Hcl	47	17
Estradiol	Estradiol	45	14
Temazepam	Temazepam	44	suppressed
Atenolol	Atenolol	42	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	11
Metformin Hcl Er	Metformin Hcl	41	15
Potassium Chloride	Potassium Chloride	41	16
Valsartan	Valsartan	41	11
Venlafaxine Hcl Er	Venlafaxine Hcl	41	suppressed
Irbesartan	Irbesartan	38	11
Aripiprazole	Aripiprazole	37	11
Glimepiride	Glimepiride	35	suppressed
Ezetimibe	Ezetimibe	34	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	34	27
Diazepam	Diazepam	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	15
Amitriptyline Hcl	Amitriptyline Hcl	32	11
Benazepril Hcl	Benazepril Hcl	31	suppressed
Glipizide	Glipizide	31	11
Mounjaro	Tirzepatide	31	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	30	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Testosterone	Testosterone	29	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Acyclovir	Acyclovir	27	13
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	27	suppressed
Nystatin	Nystatin	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Testosterone Cypionate	Testosterone Cypionate	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Methotrexate	Methotrexate Sodium	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	11
Amoxicillin	Amoxicillin	25	24
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Xarelto	Rivaroxaban	24	suppressed
Clonidine Hcl	Clonidine Hcl	23	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	11
Latanoprost	Latanoprost	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Telmisartan	Telmisartan	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Nitroglycerin	Nitroglycerin	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Doxycycline Hyclate	Doxycycline Hyclate	20	19
Progesterone	Progesterone, Micronized	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	11
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Eszopiclone	Eszopiclone	19	suppressed
Naproxen	Naproxen	19	suppressed
Baclofen	Baclofen	18	suppressed
Methocarbamol	Methocarbamol	18	suppressed
Raloxifene Hcl	Raloxifene Hcl	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Linzess	Linaclotide	15	suppressed
Premarin	Estrogens, Conjugated	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	12	suppressed
Victoza 2-Pak	Liraglutide	12	suppressed
Ztlido	Lidocaine	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Trimethoprim	Trimethoprim	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error